eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
 
1/2022
vol. 38
 
Share:
Share:
more
 
 
abstract:
Review article

Neuroscience-based Nomenclature – a paradigm shift in the classification of psychiatric drugs

Piotr Podwalski
1
,
Jerzy Samochowiec
1

1.
Department of Psychiatry, Pomeranian Medical University, Szczecin, Poland;
Katedra i Klinika Psychiatrii, Pomorski Uniwersytet Medyczny, Szczecin, Polska
Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 35–47
Online publish date: 2022/08/02
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
PlumX metrics:
Objectives
The aim of the study was to present the general rules and limitations of the proposed new system of classification of pharmacological substances used in psychiatry, i.e. Neuroscience-based Nomenclature (NbN).

Review of selected literature
Current literature on NbN and its possibilities in the classification of medicinal substances was reviewed. The currently used Anatomical Therapeutic Chemical (ATC) Classification and its limitations are presented. The structure of NbN is discussed and its practical use is described. The limitations of the NbN classification were also analysed.

Conclusions
Based on the current literature, we can conclude that the NbN classification of psychopharmaceuticals may turn out to be a breakthrough in this field. Due to its features, it is a system that is regularly updated. Thanks to the vast amount of information and the available mobile application, the NbN classification has a chance to enter everyday clinical practice.

keywords:

psychotropic drugs, nomenclature, neuroscience

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.